Vonoprazan: A novel agent used in eradicating Helicobacter pylori infection.
| Autor: | Provenza D; At Wake Forest University School of Medicine in Winston-Salem, N.C., Delaney Provenza is an assistant professor in the PA program and John Michael Provenza is an assistant professor of gastroenterology. The authors have disclosed no potential conflicts of interest, financial or otherwise., Provenza JM |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JAAPA : official journal of the American Academy of Physician Assistants [JAAPA] 2024 Dec 01; Vol. 37 (12), pp. 13-17. Date of Electronic Publication: 2024 Dec 21. |
| DOI: | 10.1097/01.JAA.0000000000000154 |
| Abstrakt: | Abstract: Helicobacter pylori is the most common chronic bacterial infection worldwide. Because of the risk for chronic gastritis, peptic ulcer disease, and gastric malignancy, all patients with H. pylori should be treated. Unfortunately, eradication rates remain low, and barriers to successful treatment include inadequate acid suppression, locoregional antibiotic resistance, and patient nonadherence to complicated treatment regimens. Vonoprazan, a new medication for the treatment of H. pylori infections, provides more potent acid suppression and is simpler to dose than proton pump inhibitors. This article provides a data-driven algorithm for incorporating vonoprazan into the treatment of patients with H. pylori infections. (Copyright © 2024 American Academy of Physician Associates.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|